Stealth BioTherapeutics


Stealth BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapies for diseases involving mitochondrial dysfunction, including rare genetic diseases and common age-related diseases. Their mission is to lead the development of mitochondrial medicine to improve patients' lives, focusing on unmet clinical needs through innovative research and collaborations. The company also offers an expanded access program to provide investigational therapies to patients with serious, life-threatening conditions when clinical trials are not feasible or suitable.

Industries

biopharma
biotechnology
pharmaceutical
therapeutics

Nr. of Employees

medium (51-250)

Stealth BioTherapeutics

Newton, Massachusetts, United States, North America


Products

Investigational mitochondria-targeted peptide (clinical-stage)

Investigational peptide designed for cell membrane penetration and targeting of the inner mitochondrial membrane to modulate cardiolipin-associated mitochondrial function; developed for ophthalmic, neuromuscular and cardiac indications.

Investigational mitochondria-targeted small molecule (early clinical / preclinical)

Small-molecule compounds designed to interact with mitochondrial pathways (cardiolipin-associated mechanisms) with preclinical neuroprotective signals and early clinical safety data.

Preclinical mitochondrial-targeted compound series

Library of follow-on and novel preclinical compounds targeting mitochondrial pathways for cardiac, skeletal muscle and neurodegenerative disease indications.


Services

Grants and sponsorships program

Provision and administration of independent medical education grants, organizational sponsorships and charitable contributions to support educational and community programs aligned with therapeutic areas.

Expanded access coordination and request evaluation

Administrative evaluation and coordination for individual patient access to investigational therapies outside of clinical trials where permitted. Process includes physician-initiated request submission, completion of a patient intake form with demographics, medical history and relevant laboratory/genetic information, eligibility assessment, and coordination of supply logistics and regulatory/ethics review. Emergency access requests may be considered via direct contact channels. Relevant protocol information is available at the referenced clinical trial registration (NCT04689360).

Scientific publications and presentations

Preparation and public dissemination of peer-reviewed articles, conference posters, slide decks and multimedia presentations describing preclinical and clinical data.

Expertise Areas

  • Mitochondrial therapeutics and mitochondrial medicine
  • Clinical trial management and operations
  • Ophthalmology clinical development (age-related macular degeneration / geographic atrophy)
  • Rare disease clinical development (e.g., genetic mitochondrial disorders)
  • Show More (4)

Key Technologies

  • Cardiolipin-interacting mitochondrial compounds
  • Mitochondria-targeted peptides and small molecules
  • Mitochondrial targeting/delivery platforms
  • Spectral-domain optical coherence tomography (SD-OCT) and ellipsoid zone mapping
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.